PPT1 and hepatocellular carcinoma: Recently, the GNS561 PPT1 inhibitor combined with anti-PD-1 was highlighted as an attractive approach to restore immune response in a transgenic immunocompetent hepatocarcinoma (HCC) mouse model [137].